close

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Its product development portfolio includes R788, which is in Phase 2b clinical trial for the treatment of rheumatoid arthritis (RA); a Phase 2 clinical trial for the treatment of immune thrombocytopenia purpura, B-cell lymphoma, and T-cell lymphoma; and a preclinical stage for the treatment of lupus. The company's products also include R348, which is in Phase 1 clinical trial for Psoriasis; R763, which is in Phase 1 clinical trial in the area of oncology; and R343, a Phase 1 clinical trial product for asthma. It has collaboration agreements with Janssen Pharmaceutica N.V.; Pfizer, Inc.; Novartis Pharma AG; Daiichi Pharmaceuticals Co., Ltd.; Merck & Co., Inc.; and Merck Serono. The company was founded in 1996 and is based in South San Francisco, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	8.58
Volume	173060
Volume Avg	299072
52 Week High	10.60
52 Week Low	6.54
PE	N/A
PE (group average)	39
EPS Year	-1.36
EPS change Q/Q	-21.21%
EPS change Q/Q Yr ago	-6.98%
EPS change Q/Q next Q est	-25%
EPS change Y/Y	1000%
REV change Q/Q	0%
REV change Q/Q Yr ago	100%
EPS next Q est	-0.32
EPS next Y est	-0.83
Divident Annual	0.00
Dividend Yield	0%